S&P ASX All Technology

US Dollar vs AUD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

VKTX Viking Therapeutics Inc

41.30

1.06 (2.63%)

After Hours

Last Updated: 10:32:31

Delayed by 15 minutes

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

10/25 selling pursuant to Rule 10b5-1 trading plan dated 05/20/2024 - POA on file

Date of Notice

10/25/2024

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

05/20/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

Sarah Kathryn Rouan

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Viking Therapeutics (NASDAQ:VKTX)
Historical Stock Chart
From Dec 2024 to Jan 2025

Click Here for more Viking Therapeutics Charts.

Viking Therapeutics (NASDAQ:VKTX)
Historical Stock Chart
From Jan 2024 to Jan 2025

Click Here for more Viking Therapeutics Charts.

Viking Therapeutics Inc News

Viking Therapeutics Presents Results from Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024
Wednesday 20 November 2024 (1 month ago) • PR Newswire (US)

Viking Therapeutics to Present Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024
Wednesday 13 November 2024 (2 months ago) • PR Newswire (US)

Form 8-K - Current report
Monday 4 November 2024 (2 months ago) • Edgar (US Regulatory)

Viking Therapeutics Reports New Data from VK2735 Obesity Program at ObesityWeek® 2024
Monday 4 November 2024 (2 months ago) • PR Newswire (US)

Tesla Sales Drop; Intel to Exit Dow Jones After 25 Years; VKTX and ATSG Surge Over 20% Pre-Market
Monday 4 November 2024 (2 months ago) • IH Market News

Viking Therapeutics to Participate at Upcoming Investor Conferences
Friday 1 November 2024 (2 months ago) • PR Newswire (US)

Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2024
Tuesday 29 October 2024 (2 months ago) • PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 26 October 2024 (2 months ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Saturday 26 October 2024 (2 months ago) • Edgar (US Regulatory)

Tesla Shares Rise 11% Pre-Market; IBM Falls 4% on Lower-Than-Expected Revenue; Apple Prepares New Launches
Thursday 24 October 2024 (2 months ago) • IH Market News

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Thursday 24 October 2024 (2 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 24 October 2024 (2 months ago) • Edgar (US Regulatory)

More Viking Therapeutics Inc News Articles

Gold vs US Dollar

Sterling vs AUD

Australia And New Zealan...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions